Polymorphic nanobody crystals as long‐acting intravitreal therapy for wet age‐related macular degeneration

Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab.

PURPOSE To evaluate the visual and anatomical outcomes of dexamethasone intravitreal implant (DXI; 700 μg, Ozurdex; Allergan, Irvine, California, USA) as adjunctive therapy for patients with refractory wet age-related macular degeneration (AMD). METHODS Retrospective review of the medical records of seven patients (seven eyes) who initially responded well to intravitreal ranibizumab but subse...

Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration.

Ranibizumab is a monoclonal antibody fragment that inhibits angiogenesis by inhibiting vascular endothelial growth factor A, used as a treatment for patients with wet aged-related macular degeneration (ARMD). Adverse effects from intravitreal Ranibizumab injections are well recognised. Macular hole formation following Ranibizumab injection is a complication that has been recently reported in fe...

Wet Age Related Macular Degeneration

Age related macular degeneration (AMD) is the leading cause of blindness in the developed countries. Approximately 8 million people in America have AMD and the number of advanced AMD is likely to rise by 50% by year 2020 due to the projected increase in the number of elderly people (Friedman et al., 2004). AMD is a condition of significant morbidity in terms of both physical and mental health (...

Intravitreal therapy in bilateral neovascular age-related macular degeneration.

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration

Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the patient is treated in t...